Janwillem Naesens - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2021
Net transactions value
$0
Form type
3
Filing time
17 Jun 2021, 21:40:29 UTC
Next filing
24 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Series B Convertible Preferred Stock 17 Jun 2021 Common Stock 2,933,581 See Footnote F1, F3
holding CYT Series C Convertible Preferred Stock 17 Jun 2021 Common Stock 325,442 See Footnote F2, F3
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 17,250 $18.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Series B Convertible Preferred Stock are convertible into the number of shares of the Issuer's common stock shown in column 3 and have no expiration date. The Series B Convertible Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F2 The shares of Series C Convertible Preferred Stock are convertible into the number of shares of the Issuer's common stock shown in column 3 and have no expiration date. The Series C Convertible Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F3 Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by Janwillem Naesens) and IHL SA (represented by the Reporting Person), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. The Reporting Person, along with Mr. Verelst, disclaim beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein.
F4 The option will vest in full on the earlier of (a) June 17, 2022 and (b) the next annual meeting of stockholders that follows June 17, 2021, in each case subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney